Tightening the tumor-targeting abilities of checkpoint blockade immunotherapy
Date | 12th, Jul 2019 |
---|---|
Source | EurekAlert - Scientific News Websites |
DESCRIPTION
Seeking to improve upon existing checkpoint inhibitor therapies, scientists have developed a common checkpoint inhibitor (anti-PD-L1) in a nanoparticle formulation, which were activated specifically at tumor sites in mouse models of cancer.